Fig. 4: Survival endpoints in the intent-to-treat population.

a Overall (hematologic and/or vital organ) progression-free survival (investigator assessed)—defined as time from randomization to first documentation of hematologic disease progression or vital organ (heart or kidney) progression, or death due to any cause, whichever occurred first. Patients without documentation of hematologic disease progression and organ progression were censored at the date of last hematologic response assessment that was stable disease or better, or the date of last organ assessment of stable disease or better, whichever occurred last. b Overall survival—defined as time from randomization to date of death. Patients without documentation of death at the time of analysis were censored at the date last known to be alive. CI confidence interval, HR hazard ratio, NE not estimable.